Position in ABBV
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$29,038,274,100
New position
Shares Held
115,396,098
first reported quarter
Ownership
6.53%
of shares outstanding
% of Portfolio
0.62%
of 13F equity value
Holder Rank
#2
of 4,152 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026VANGUARD CAPITAL MANAGEMENT LLC holds $204,413,082,896 across 13 Drug Manufacturers - General names. ABBV ranks #3 (14.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
53,528,868 | $64,204,135,498 | |
| 2 | JNJ |
Johnson & Johnson
|
157,226,374 | $39,930,782,204 | |
| 3 | ABBV |
AbbVie Inc.
This page
|
115,396,098 | $29,038,274,100 | |
| 4 | MRK |
Merck & Co., Inc.
|
161,323,174 | $20,730,027,859 | |
| 5 | AMGN |
Amgen Inc
|
35,250,101 | $12,764,766,574 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
81,091,734 | $10,245,129,673 | |
| 7 | PFE |
Pfizer Inc
|
372,149,852 | $8,961,368,436 | |
| 8 | AZN |
Astrazeneca PLC
|
45,386,190 | $8,606,129,347 |
All Filings in ABBV
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $29,038,274,100 | 115,396,098 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $28,909,653,374 | 132,924,058 | Shares | Sole | 2026-04-29 | |
| No filing history on record for this holder in this stock. | ||||||